文献速递妇科

重新界定卵巢癌细胞系COV434与TOV-112D的组织学身份

Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines.
PubMed 文献 · Gynecol Oncol · 2020-12-13

该研究通过复核原始病理切片、免疫组化、基因测序及体内外实验,重新界定COV434和TOV-112D的组织学来源。结果提示COV434来源于卵巢高钙血症型小细胞癌(SCCOHT),TOV-112D为去分化癌;两者重新表达SMARCA4后生长均受显著抑制。

要点

  • COV434应被认定为SCCOHT细胞系,而非原述的颗粒细胞瘤。
  • TOV-112D应被认定为去分化卵巢癌,而非原述的子宫内膜样癌。
  • 两细胞系重新表达SMARCA4后生长均受显著抑制。

核心结论

  • COV434是真正的SCCOHT细胞系,TOV-112D是去分化卵巢癌细胞系。

研究设计与样本

  • 对COV434和TOV-112D复核原始病理切片并获取患者临床随访。
  • 对可获得的FFPE临床材料行SMARCA4、SMARCA2及其他诊断标志物免疫组化。
  • 对COV434行全外显子测序并用Sanger测序验证SMARCA4突变。
  • 体外研究两细胞系基线及重新表达SMARCA4后的生长。
  • 将COV434注入免疫缺陷小鼠并评估血清钙水平。

主要发现

  • 形态学、免疫组化、遗传学及临床特征提示COV434来源于SCCOHT。
  • 形态学、免疫组化、遗传学及临床特征提示TOV-112D为去分化癌。
  • COV434移植入小鼠后导致血清钙水平升高。
  • COV434和TOV-112D细胞重新表达SMARCA4后生长均受显著抑制。

临床怎么用

  • 使用COV434作为SCCOHT模型时,应明确其组织学身份为SCCOHT。
  • 使用TOV-112D作为去分化卵巢癌模型时,应避免将其误认为子宫内膜样癌。
  • SMARCA4重新表达抑制生长的结果支持SMARCA4在两者中的功能相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The development of effective cancer treatments depends on the availability of cell lines that faithfully recapitulate the cancer in question. This study definitively re-assigns the histologic identities of two ovarian cancer cell lines, COV434 (originally described as a granulosa cell tumour) and TOV-112D (originally described as grade 3 endometrioid carcinoma), both of which were recently suggested to represent small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), based on their shared gene expression profiles and sensitivity to EZH2 inhibitors. METHODS: For COV434 and TOV-112D, we re-reviewed the original pathology slides and obtained clinical follow-up on the patients, when available, and performed immunohistochemistry for SMARCA4, SMARCA2 and additional diagnostic markers on the original formalin-fixed, paraffin-embedded (FFPE) clinical material, when available. For COV434, we further performed whole exome sequencing and validated SMARCA4 mutations by Sanger sequencing. We studied the growth of the cell lines at baseline and upon re-expression of SMARCA4 in vitro for both cell lines and evaluated the serum calcium levels in vivo upon injection into immunodeficient mice for COV434 cells. RESULTS: The available morphological, immunohistochemical, genetic, and clinical features indicate COV434 is derived from SCCOHT, and TOV-112D is a dedifferentiated carcinoma. Transplantation of COV434 into mice leads to increased serum calcium level. Re-expression of SMARCA4 in either COV434 and TOV-112D cells suppressed their growth dramatically. CONCLUSIONS: COV434 represents a bona fide SCCOHT cell line. TOV-112D is a dedifferentiated ovarian carcinoma cell line.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Karnezis AN, Chen SY, Chow C, et al. Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecol Oncol. 2020. PMID: 33328126. doi:10.1016/j.ygyno.2020.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。